(for veterinary information only)
BRAND NAME: PALLADIA
This medication was developed to address the mast cell tumor in dogs. Normal mast cells line the body’s interfaces with the outside world (skin, respiratory tract, etc.) and become bound by antibodies directed against invading parasites. When a mast cell coated with antibodies meets a parasitic protein, a reaction occurs whereby the mast cell “degranulates” which means it releases its stored inflammatory proteins. These inflammatory mediators help destroy the invader.
When mast cells become tumorous, they degranulate spontaneously creating inappropriate tissue inflammation. When mast cell tumors are malignant, they can spread through the body creating a highly inflammatory form of cancer. Mast cells tumor malignancy is commonly graded 1, 2, or 3, with 3 being the most highly invasive and malignant form.
Toceranib phosphate was developed for use against grade 2 and grade 3 mast cell tumors. Toceranib phosphate is what is called a “tyrosine kinase inhibitor.” It has two actions against the mast cell tumor: first it kills the tumor cells directly and second, it interferes with the tumor’s blood supply.
Since its release and success against the mast cell tumor, much research has been conducted using toceranib phosphate against an assortment of other tumors, particularly those not generally amenable to other types of chemotherapy agents. Tumors that have found to show a notable response to this medication include:
Research is continuing to determine new uses for this relatively unique medical approach to cancer.
HOW THIS MEDICATION IS USED
Toceranib phosphate is a tablet usually given every other day. Monitoring blood tests are periodically recommended.
The most common side effects of toceranib phosphate include:
Notify your veterinarian if any of the above occurs.
Blood test monitoring may reveal anemia (deficiency of red blood cells), drop in neutrophil (a type of white blood cell) count, increase in renal toxin build up (azotemia), elevated blood phosphate, or drop in blood albumin level. Any of these changes warrant temporary discontinuation of the medication.
Since the commercial release of toceranib phosphate, three other conditions have emerged as potential side effects: renal (kidney) protein loss, liver disease, and pancreatitis. The first two issues listed are reportedly manageable with medication allowing for reinstitution of toceranib phosphate at a lower dose. Pancreatitis is also treatable but recurrence may be severe enough not to warrant risk with continued use of toceranib phosphate.
Embolic disease (abnormal blood clotting) were the most common problem considered to be possibly drug related during initial testing of this drug. One of the test dogs died from a perforated stomach thus is it is especially important to watch for intestinal signs and address them promptly.
Some dogs have depigmentation of their nose or fur during treatment with toceranib phosphate.
INTERACTIONS WITH OTHER DRUGS
Use of toceranib phosphate with non-steroidal anti-inflammatory drugs can increase the risk of intestinal bleeding. That said, it is not unusual to combine toceranib phosphate with piroxicam, a non-steroidal anti-inflammatory agent that has anti-tumor properties. In this situation, medications are given on alternating days and the combination seems to be well tolerated.
CONCERNS AND CAUTIONS
The manufacturer of toceranib phosphate (Zoetis, formerly Pfizer Animal Health) has created this client information sheet/product insert and recommends that it accompany each prescription:
More information can also be located at:
Page posted: 7/17/2011